Immune Discovery & Modeling Service (IDMS): Publications

Immune Discovery & Modeling Service (IDMS): Publications

Share
Share

View a full listing of Immune Discovery & Modeling Service (IDMS): Publications’ journal articles.

Recent publications from our team.

Key Publications and Presentations by our team:

 

Papers:

Durable Engraftment and Excellent Overall Survival After CD34-Selected Peripheral Blood Stem Cell Boost in Pediatric Patients With Poor Graft Function Following Allogeneic Stem Cell Transplantation.

Fraint E, Farooki S, Klein E, Mauguen A, Prockop SE, Scaradavou A, Curran K, Cancio M, Spitzer B, Boelens JJ, Oved J, Harris A, O’Reilly RJ, Kernan NA.Transplant Cell Ther. 2023 Jan;29(1):46.e1-46.e6. doi: 10.1016/j.jtct.2022.09.027. Epub 2022 Oct 6. PMID: 36210027

GPRC5D-Targeted CAR T Cells for Myeloma.

Mailankody S, Devlin SM, Landa J, Nath K, Diamonte C, Carstens EJ, Russo D, Auclair R, Fitzgerald L, Cadzin B, Wang X, Sikder D, Senechal B, Bermudez VP, Purdon TJ, Hosszu KMcAvoy DP, Farzana T, Mead E, Wilcox JA, Santomasso BD, Shah GL, Shah UA, Korde N, Lesokhin A, Tan CR, Hultcrantz M, Hassoun H, Roshal M, Sen F, Dogan A, Landgren O, Giralt SA, Park JH, Usmani SZ, Rivière I, Brentjens RJ, Smith EL.N Engl J Med. 2022 Sep 29;387(13):1196-1206. doi: 10.1056/NEJMoa2209900.PMID: 36170501 Clinical Trial.

Sustained Minimal Residual Disease Negativity in Multiple Myeloma is Associated with Stool Butyrate and Healthier Plant-Based Diets.

Shah UA, Maclachlan KH, Derkach A, Salcedo M, Barnett K, Caple J, Blaslov J, Tran L, Ciardiello A, Burge M, Shekarkhand T, Adintori P, Cross J, Pianko MJ, Hosszu KMcAvoy D, Mailankody S, Korde N, Hultcrantz M, Hassoun H, Tan CR, Lu SX, Patel D, Diamond B, Shah G, Scordo M, Lahoud O, Chung DJ, Landau H, Usmani SZ, Giralt S, Taur Y, Landgren CO, Block G, Block T, Peled JU, van den Brink MRM, Lesokhin AM.Clin Cancer Res. 2022 Dec 1;28(23):5149-5155. doi: 10.1158/1078-0432.CCR-22-0723.PMID: 36170461

MAIT and Vδ2 unconventional T cells are supported by a diverse intestinal microbiome and correlate with favorable patient outcome after allogeneic HCT.

Andrlová H, Miltiadous O, Kousa AI, Dai A, DeWolf S, Violante S, Park HY, Janaki-Raman S, Gardner R, El Daker S, Slingerland J, Giardina P, Clurman A, Gomes ALC, Nguyen C, da Silva MB, Armijo GK, Lee N, Zappasodi R, Chaligne R, Masilionis I, Fontana E, Ponce D, Cho C, Bush A, Hill L, Chao N, Sung AD, Giralt S, Vidal EH, Hosszu KK, Devlin SM, Peled JU, Cross JR, Perales MA, Godfrey DI, van den Brink MRM, Markey KA. Sci Transl Med. 2022 May 25;14(646):eabj2829. doi: 10.1126/scitranslmed.abj2829. Epub 2022 May 25.PMID: 35613281

Therapeutic Drug Monitoring of Anti-Thymocyte Globulin in Allogeneic Stem Cell Transplantation: Proof of Concept.

Meesters-Ensing JI, Admiraal R, Ebskamp L, Lacna A, Boelens JJ, Lindemans CA, Nierkens S.Front Pharmacol. 2022 Mar 18;13:828094. doi: 10.3389/fphar.2022.828094. eCollection 2022.PMID: 35370695 

Individualised dosing of anti-thymocyte globulin in paediatric unrelated allogeneic haematopoietic stem-cell transplantation (PARACHUTE): a single-arm, phase 2 clinical trial.

Admiraal R, Nierkens S, Bierings MB, Bredius RGM, van Vliet I, Jiang Y, Lopez-Yurda M, Versluijs AB, Zwaan CM, Lindemans CA, Boelens JJ.Lancet Haematol. 2022 Feb;9(2):e111-e120. doi: 10.1016/S2352-3026(21)00375-6.PMID: 35114150 Clinical Trial.

Early intestinal microbial features are associated with CD4 T-cell recovery after allogeneic hematopoietic transplant.

Miltiadous O, Waters NR, Andrlová H, Dai A, Nguyen CL, Burgos da Silva M, Lindner S, Slingerland J, Giardina P, Clurman A, Armijo GK, Gomes ALC, Lakkaraja M, Maslak P, Scordo M, Shouval R, Staffas A, O’Reilly R, Taur Y, Prockop S, Boelens JJ, Giralt S, Perales MA, Devlin SM, Peled JU, Markey KA, van den Brink MRM.Blood. 2022 May 5;139(18):2758-2769. doi: 10.1182/blood.2021014255.PMID: 35061893

Antithymocyte globulin exposure in CD34+ T-cell-depleted allogeneic hematopoietic cell transplantation.

Lakkaraja M, Scordo M, Mauguen A, Cho C, Devlin S, Ruiz JD, Klein E, Avecilla ST, Boulad F, Cancio MI, Curran KJ, Jakubowski AA, Kernan NA, Kung AL, O’Reilly RJ, Papadopoulos EB, Prockop S, van Roessel I, Scaradavou A, Shaffer BC, Shah G, Spitzer B, Tamari R, Giralt SA, Perales MA, Boelens JJ.Blood Adv. 2022 Feb 8;6(3):1054-1063. doi: 10.1182/bloodadvances.2021005584.PMID: 34788361 

Immune Monitoring during Therapy Reveals Activitory and Regulatory Immune Responses in High-Risk Neuroblastoma.

Szanto CL, Cornel AM, Tamminga SM, Delemarre EM, de Koning CCH, van den Beemt DAMH, Dunnebach E, Tas ML, Dierselhuis MP, Tytgat LGAM, van Noesel MM, Kraal KCJM, Boelens JJ, Huitema ADR, Nierkens S.Cancers (Basel). 2021 Apr 26;13(9):2096. doi: 10.3390/cancers13092096.PMID: 33926057 

Harmonization, biomarkers, disease risk index.

Boelens JJ.Blood. 2021 Feb 18;137(7):874-875. doi: 10.1182/blood.2020009862.PMID: 33599765 

CD4+ T-cell reconstitution predicts survival outcomes after acute graft-versus-host-disease: a dual-center validation.

de Koning C, Prockop S, van Roessel I, Kernan N, Klein E, Langenhorst J, Szanto C, Belderbos M, Bierings M, Boulad F, Bresters D, Cancio M, Curran K, Kollen W, O’Reilly R, Scaradavou A, Spitzer B, Versluijs B, Huitema A, Lindemans C, Nierkens S, Boelens JJ.Blood. 2021 Feb 11;137(6):848-855. doi: 10.1182/blood.2020007905.PMID: 33150379 

Immune Monitoring After Allogeneic Hematopoietic Cell Transplantation: Toward Practical Guidelines and Standardization.

Boelens JJHosszu KK, Nierkens S.Front Pediatr. 2020 Aug 21;8:454. doi: 10.3389/fped.2020.00454. eCollection 2020.PMID: 32974239 

Early CD4+ T cell reconstitution as predictor of outcomes after allogeneic hematopoietic cell transplantation.

van Roessel I, Prockop S, Klein E, Boulad F, Scaradavou A, Spitzer B, Kung A, Curran K, O’Reilly RJ, Kernan NA, Cancio M, Boelens JJ.Cytotherapy. 2020 Sep;22(9):503-510. doi: 10.1016/j.jcyt.2020.05.005. Epub 2020 Jul 1.PMID: 32622752

Oral Presentations:

Impact of Rabbit Anti-Thymocyte Globulin (rATG) Exposure in Ex Vivo T-Cell Depleted Hematopoietic Cell Transplantation in Children and Young Adults.

Lakkaraja M., Mauguen A., Boulad F., Cancio M.I., Curran K.J., Harris A., Kernan N.A., Klein E., Kung A.L., Oved J.H., Prockop S., Scaradavou A., Spitzer B., O’Reilly R.J., Boelens J.J. “Oral Presentation: 2023 Tandem Meetings Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, Orlando, Florida, February 2023.

Decreased neuroprotective analytes on day of infusion of chimeric antigen receptor (car) T cells are associated with neurotoxicity.

Lakkaraja M., Hosszu K., McAvoy D., Mauguen A., Purdon T.J., Khakoo Y., Santomasso B.D., Riviere I., Sadelain M., Curran K.J., Park J.H., Brentjens R.J., Boelens J.J. Oral Presentation: 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), March 2021.

Rabbit Anti-Thymocyte Globulin (ATG) Exposure after Ex Vivo T-Cell Depleted Hematopoietic Cell Transplantation Is Variable and Impacts Immune Reconstitution and Survival in Pediatric and Young Adult Patients.

Lakkaraja, M., Mauguen, A., Boulad, F., Spitzer, B., Scaradavou, A., Curran, K.J., Cancio, M.I., Roessel, I., Klein, E., Kernan, N.A., O’Reilly, R., Prockop, S. and Boelens, J.J. Oral Presentation: 46th Annual Meeting of the European Society for Blood and Marrow Transplantation, August 2020.

Posters: 

Discovery Proteomics for Analytes to predict Cytokine Release Syndrome on Day of Infusion of Chimeric Antigen Receptor (CAR) T cells.

Lakkaraja M., Hosszu K., McAvoy D., Mauguen A., Purdon T.J., Khakoo Y., Santomasso B.D., Senechal B.,Riviere I., Sadelain M., Curran K.J., Park J.H., Brentjens R.J., Boelens J.J.. Poster presentation: International Society for Cell & Gene Therapy (ISCT) 2022, San Francisco, May 2022.

Predictors for Neurotoxicity on Day of Infusion of Chimeric Antigen Receptor (CAR) T cells using Discovery Proteomics Platform. 

Lakkaraja M., Hosszu K., McAvoy D., Mauguen A., Purdon T.J., Khakoo Y., Santomasso B.D., Senechal B.,Riviere I., Sadelain M., Curran K.J., Park J.H., Brentjens R.J., Boelens J.J.. Late Breaking abstract. Poster presentation: International Society for Cell & Gene Therapy (ISCT) 2021, May 2021  

Rabbit Anti-Thymocyte Globulin Exposure (rATG) in CD34+ Selected Hematopoietic Cell Transplantation and Its Impact on Immune Reconstitution and Outcomes in Children and Adults.

Lakkaraja, M., Scordo, M., Mauguen, A., Cho C., Devlin S., Avecilla S., Boulad F., Cancio, M., Curran, K., Jakubowski, A., Kernan N, Kung A., O’Reilly R., Papadopoulos E., Prockop S., Roessel I., Ruiz J., Scaradavou, A., Shaffer B., Shah G., Spitzer B., Tamari R., Giralt S., Perales MA, Boelens JJ. Poster presentation: 2020 American Society of Hematology (ASH) December 5, 2020.

Rabbit Anti-Thymocyte Globulin (ATG) Exposure after Ex Vivo T-Cell Depleted Hematopoietic Cell Transplantation Is Highly Variable and Impacts Immune Reconstitution in Pediatric and Young Adult Patients.

Lakkaraja, M., Mauguen, A., Boulad, F., Spitzer, B., Scaradavou, A., Curran, K.J., Cancio, M.I., Roessel, I., Kernan, N.A., O’Reilly, R., Prockop, S. and Boelens, J.J. Poster presentation: 2020 Transplantation and Cellular Therapy         Meetings of American Society of ASTCT and the CIBMTR. February 19, 2020, Orlando, Florida.